JP2006525373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525373A5 JP2006525373A5 JP2006514314A JP2006514314A JP2006525373A5 JP 2006525373 A5 JP2006525373 A5 JP 2006525373A5 JP 2006514314 A JP2006514314 A JP 2006514314A JP 2006514314 A JP2006514314 A JP 2006514314A JP 2006525373 A5 JP2006525373 A5 JP 2006525373A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- immunogenic composition
- liposaccharide
- derived
- proteosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 70
- 230000002163 immunogen Effects 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 53
- 108091007433 antigens Proteins 0.000 claims 53
- 102000036639 antigens Human genes 0.000 claims 53
- 239000002671 adjuvant Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 5
- 230000000813 microbial effect Effects 0.000 claims 5
- 241000193738 Bacillus anthracis Species 0.000 claims 4
- 229940065181 bacillus anthracis Drugs 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 244000005700 microbiome Species 0.000 claims 4
- 241000588653 Neisseria Species 0.000 claims 3
- 241000607479 Yersinia pestis Species 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 241000710929 Alphavirus Species 0.000 claims 2
- 241000712891 Arenavirus Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims 2
- 241000193468 Clostridium perfringens Species 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 241000713112 Orthobunyavirus Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 101710194807 Protective antigen Proteins 0.000 claims 2
- 241000607762 Shigella flexneri Species 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108030001720 Bontoxilysin Proteins 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims 1
- 241000607000 Plesiomonas Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Claims (43)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46762403P | 2003-05-05 | 2003-05-05 | |
PCT/US2004/014236 WO2004098636A2 (en) | 2003-05-05 | 2004-05-05 | Vaccinating against infectious diseases using proteosomes |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006525373A JP2006525373A (en) | 2006-11-09 |
JP2006525373A5 true JP2006525373A5 (en) | 2007-06-28 |
Family
ID=33435094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006514314A Withdrawn JP2006525373A (en) | 2003-05-05 | 2004-05-05 | Vaccination against infectious diseases using proteosomes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1622641A2 (en) |
JP (1) | JP2006525373A (en) |
AU (1) | AU2004235815A1 (en) |
CA (1) | CA2524485A1 (en) |
WO (1) | WO2004098636A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255867B2 (en) | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
US8173140B2 (en) | 2003-10-22 | 2012-05-08 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
US20080226729A1 (en) * | 2006-09-08 | 2008-09-18 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001045639A2 (en) * | 1999-12-22 | 2001-06-28 | The Ohio State University Research Foundation | Methods for protecting against lethal infection with bacillus anthracis |
AU2002245636B2 (en) * | 2001-03-09 | 2004-10-14 | Id Biomedical Corporation Of Quebec | A novel proteosome-liposaccharide vaccine adjuvant |
-
2004
- 2004-05-05 EP EP04760725A patent/EP1622641A2/en not_active Withdrawn
- 2004-05-05 WO PCT/US2004/014236 patent/WO2004098636A2/en not_active Application Discontinuation
- 2004-05-05 AU AU2004235815A patent/AU2004235815A1/en not_active Abandoned
- 2004-05-05 CA CA002524485A patent/CA2524485A1/en not_active Abandoned
- 2004-05-05 JP JP2006514314A patent/JP2006525373A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yamamoto et al. | A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A | |
Plotkin et al. | The development of vaccines: how the past led to the future | |
Weimer et al. | Immunization of young African green monkeys with OprF epitope 8–OprI–type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonasaeruginosa | |
Holder | Pseudomonas immunotherapy: a historical overview | |
JP2018523668A5 (en) | ||
Naito et al. | The protective effects of nasal PcrV‐CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia | |
EP2928491A1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
JP2015536134A5 (en) | ||
Kondakova et al. | Vaccines against anthrax based on recombinant protective antigen: problems and solutions | |
Tadepalli et al. | Immunogenicity and protective efficacy of Brucella abortus recombinant protein cocktail (rOmp19+ rP39) against B. abortus 544 and B. melitensis 16M infection in murine model | |
RU2010130338A (en) | MUTANT STREPTOLYSINE FORMS ABOUT | |
Esmaeilkhani et al. | In vivo validation of the immunogenicity of recombinant baumannii acinetobactin utilization a protein (rBauA) | |
Whitlock et al. | Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge | |
Ranasinghe | New advances in mucosal vaccination | |
McComb et al. | Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine | |
Das et al. | Development of a broadly protective, self-adjuvanting subunit vaccine to prevent infections by Pseudomonas aeruginosa | |
Verma et al. | A recombinant trivalent fusion protein F1–LcrV–HSP70 (II) augments humoral and cellular immune responses and imparts full protection against Yersinia pestis | |
ES2444693T3 (en) | Enterococcus derived polypeptide and its use for vaccination | |
Sharma et al. | Immune response characterization and vaccine potential of a recombinant chimera comprising B-cell epitope of Aeromonas hydrophila outer membrane protein C and LTB | |
Lavender et al. | Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease | |
JP2006525373A5 (en) | ||
JP2007509166A5 (en) | ||
Tadepalli et al. | Intraperitoneal administration of a novel chimeric immunogen (rOP) elicits IFN-γ and IL-12p70 protective immune response in BALB/c mice against virulent Brucella | |
He et al. | Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity | |
Lo et al. | Antibody responses of calves to Histophilus somni recombinant IbpA subunits |